ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.
Saad MI, Alhayyani S, McLeod L, Yu L, Alanazi M, Deswaerte V, Tang K, Jarde T, Smith JA, Prodanovic Z, Tate MD, Balic JJ, Watkins DN, Cain JE, Bozinovski S, Algar E, Kohmoto T, Ebi H, Ferlin W, Garbers C, Ruwanpura S, Sagi I, Rose-John S, Jenkins BJ.
Saad MI, et al. Among authors: deswaerte v.
EMBO Mol Med. 2019 Apr;11(4):e9976. doi: 10.15252/emmm.201809976.
EMBO Mol Med. 2019.
PMID: 30833304
Free PMC article.